Utah Medical Products, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019
January 30, 2020 at 10:03 am EST
Share
Utah Medical Products, Inc. announced earnings results for the fourth quarter ended December 31, 2019. For the fourth quarter, the company announced sales was USD 11.831 million compared to USD 9.756 million a year ago. Operating income was USD 4.679 million compared to USD 4.269 million a year ago. Net income was USD 4.359 million compared to USD 3.393 million a year ago. Basic earnings per share was USD 1.165 compared to USD 0.905 a year ago. For the full year, sales was USD 46.904 million compared to USD 41.998 million a year ago. Operating income was USD 17.633 million compared to USD 18.697 million a year ago. Net income was USD 14.727 million compared to USD 18.555 million a year ago. Basic earnings per share was USD 3.939 compared to USD 4.95 a year ago.
Utah Medical Products, Inc. is engaged in the business of producing medical services. The Company markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit (NICU), the labor and delivery (L&D) department and the women's health center in hospitals, as well as medical devices sold to outpatient clinics and physician's offices. Its products include BT-CATH, CVX-RIPE, AROM-COT, MUC-X, CORDGUARD, DISPOSA-HOOD, DELTRAN PLUS, GESCO, PICC-NATE, LETZ System, Filshie Clip System, PATHFINDER PLUS, SUPRAPUBIC CATHETERIZATION, LIBERTY System, ENDOCURETTE, LUMIN, and BioPharm HP-PRT, among others. BT-CATH is a uterine balloon tamponade catheter for controlling severe postpartum hemorrhage. MUC-X is an aspiration device used immediately after birth to clear neonatal respiratory passages and reduce exposure to potential infections. AROM-CO is a finger cover with a prong designed to rupture maternal membranes with less patient pain and anxiety.
UTAH MEDICAL PRODUCTS, INC. 
